Investment Summary |
|
|---|---|
| Date | 2007-05-23 |
| Target | Prolacta Bioscience |
| Sector | Life Science |
| Investor(s) | Alta Partners |
| Deal Type | Venture |
SEARCH BY
| Category | Venture Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 2.6B USD |
| Size | Large |
| Type | Sector Focused |
Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 38 of 59 |
| Sector: Life Science M&A | 32 of 50 |
| Type: Venture M&A Deals | 32 of 48 |
| Country: Australia M&A | 1 of 1 |
| Year: 2007 M&A | 5 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-05-15 |
Insulet
Acton, Massachusetts, United States Insulet is a medical device company, which develops and manufactures insulin infusion systems for people with insulin-dependent diabetes. Insulet was founded in 2000 and is based in Acton, Massachusetts. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-11-07 |
Ablynx NV
Zwijnaarde, Belgium Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a new class of antibody-derived therapeutics for inflammation, cancer, blood and lung disease. The company currently has more than 30 products under development in its product pipeline. Ablynx was formed in 2001 and is based in Ghent, Belgium. |
Sell | - |
